Physician profile
Derrick K Abe
NPI 1184676264
$8,684.77
in general payments reported to CMS, 2019-2025
19 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $267 · 2021: $1,268 · 2022: $1,275 · 2023: $1,583 · 2024: $1,252 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Entertainment: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.43 |
| Entertainment | $141.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,846.30 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Alcon Vision LLC | $1,426.04 | 2019-2025 | Total30, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,288.79 | 2019-2021 | |
| Coopervision INC. | $963.55 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $571.96 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $558.44 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $419.47 | 2019-2025 | Acuvue |
| Horizon Therapeutics Plc | $335.66 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $242.37 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $226.39 | 2021-2022 | |
| Lombart Brothers, INC. | $141.19 | 2025 | Opd-III |
| Shire North American Group INC | $140.78 | 2019 | |
| Amgen INC. | $134.97 | 2025 | Tepezza |
| Lkc Technologies, INC. | $129.56 | 2023-2024 | |
| Allergan, INC. | $95.35 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.27 | 2022-2025 | Lumigan |
| Novartis Pharmaceuticals Corporation | $34.24 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Abe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.